Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday

What happened

Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (NASDAQ: ARWR) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial. Arrowhead's shares are down more than 13% this year but up more than 45% this month.

The company focuses on experimental RNA-based therapies that can block the production of proteins that can cause medical disorders. Arrowhead's therapies use the RNA interference mechanism to quickly and durably knock down certain target genes.

So what

Arrowhead released interim results from its ARO-RAGE phase 1/2 trial that showed 90% serum receptor for advanced glycation end products (RAGE) reduction and 80% RAGE reduction with mean maximum reduction after two doses. The protein RAGE is connected to several inflammatory diseases, including asthma.

The company said it plans to announce more details from the trial at the company's research and development day on June 1.

Now what

Arrowhead has had a big month.

  • On April 3, the company said it had earned a $30 million milestone payment from GSK regarding Arrowhead's former investigational RNA therapy, ARO-HSD, now called GSK4532990. It just entered a phase 2 trial to treat patients with non-alcoholic steatohepatitis (NASH).
  • One day later, the company said it was picking up a $40 million milestone payment from Takeda Pharmaceutical because fazirsiran, developed by Arrowhead, was entering a phase 3 trial to treat alpha-1 antitrypsin deficiency associated liver disease.

Those payments will add to momentum for the stock. The company reported first-quarter revenue of $62.5 million, up 128% year over year, and an earnings-per-share (EPS) loss of $0.39, compared to an EPS loss of $0.60 in the same period a year ago. Arrowhead is scheduled to report second-quarter financials on May 2.

Arrowhead also should soon benefit if cardiovascular therapy olpasiran is approved by the Food and Drug Administration. The company has the potential for $400 million in various milestone payments from Amgen regarding the therapy that Arrowhead developed. The drug is in a phase 3 trial.

10 stocks we like better than Arrowhead Pharmaceuticals
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Arrowhead Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of April 24, 2023

Jim Halley has positions in GSK. The Motley Fool recommends Amgen and GSK. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.